256840.KQ
256840.KQ
KR7256840000
BNC
Loading chart...

Company Profile

BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia. It also provides HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration; Hibarry, a bio-absorbable gel and solution mixture used to prevent adhesion of the spinal cord post-surgery; and GentaQ a beauty face, and home and other care products under the I.st name. The company was formerly known as BNC Korea Co., Ltd. and changed its name to BNC KOREA, Inc. in April 2026. The company also exports its products to 45 countries. BNC KOREA, Inc. was incorporated in 2007 and is headquartered in Daegu, South Korea.

Related stocks

003850.KS
003850.KS • South Korea
Boryung
8,610 KRW
525.24M USD 1Y +0.2%
068760.KQ
068760.KQ • South Korea
Celltrionph
38,800 KRW
1.28B USD 1Y -27.1%
195940.KQ
195940.KQ • South Korea
HK inno.N
39,700 KRW
839.31M USD 1Y -13.3%
006280.KS
006280.KS • South Korea
GC Biopharma Corp.
129,400 KRW
1.1B USD 1Y -2.2%
009420.KS
009420.KS • South Korea
HANALL BIOPHARMA
44,000 KRW
1.67B USD 1Y +26.4%
185750.KS
185750.KS • South Korea
CHONGKUNDANG
65,900 KRW
647.98M USD 1Y -19.9%
BLISSGVS.BO
BLISSGVS.BO • India
BLISS GVS PHARMA LTD.
644.55 INR
708.16M USD 1Y +341.4%
MOREPENLAB.NS
MOREPENLAB.NS • India
MOREPEN LAB. LTD
129.55 INR
733.49M USD 1Y +170.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
72.0% p.a.
Max Drawdown (5Y)
-93.4%
Sharpe Ratio (5Y)
-0.49
Beta Factor
1.07
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (72.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -96.3% in the extended horizon.
ende